JCP Editors

The ASH Annual Meeting & Exposition remains an exciting learning ground for advancements within the specialty. This year’s meeting featured more than 400 abstract presentations, lectures, panels, and discussions.
This year marked the 40th anniversary of the San Antonio Breast Cancer Symposium (SABCS), which has been a mainstay meeting in the field of breast cancer since 1977.Research and lectures presented at SABCS influence the treatment of women and men with breast cancer around the world.

Multiple Myeloma, Lymphoma Respond Differently to Treatment for Anemia

A comparative effectiveness study analyzed response to anemia supportive treatment for patients with multiple myeloma or lymphoma.

Read More

 

Health Care Utilization High for Hospitalized Patients With Advanced Cancer

The ACCC held their 34th National Oncology Conference in Nashville, TN, from October 18 to October 20, which highlighted advances in the treatment and care of patients with multiple different types of cancers, as well as issues germane to practice within the community oncology sphere.

Clinical Pathways for Myeloid Growth Factors Lead to Appropriate Use

A poster presentation at AMCP Nexus 2017 found that the implementation of a clinical pathway increased the appropriate use of myeloid growth factors for patients receiving myelosuppressive cancer chemotherapy.

Read More

 

Recent research has shown which immuno-agent to be effective with limited toxicity in advanced soft-tissue and bone sarcoma?
A recent study showed that after performing next-generation sequencing of non-small cell lung cancer gene panels, actionable mutations were identifiable in 65% of cases with available targeted therapeutic options.
A recent comparative study examined predictors of discharge location for patients with advanced cancer and assessed the relationship between discharge location and survival.
Twenty-four-month event-free survival may be a surrogate for overall survival in patients with peripheral T-cell lymphoma, according to a recent study.
The US Food and Drug Administration has approved the supplemental New Drug Application for alectinib as a first-line treatment for patients with a specific type of lung cancer.